TICKERNERD
Menu
AKBAAKBAHealthcare · Drug Manufacturers - Specialty & Generic

AKBA Stock Forecast: Akebia Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$0.91
−1.22% on the day

The 5 Wall Street analysts covering Akebia Therapeutics, Inc. hold a median 12-month price target of $4 — +340.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 75 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$254.8M
Ticker Nerd rank
75 / 100
Median analyst target
$4.00
Analysts covering
5
Total return, dividends reinvested
1W
+4.0%
1M
−30.1%
YTD
−43.6%
1Y
−71.5%
From 52W high
−71.5%
From 52W low
+7.6%
$0.84
$3.19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AKBA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Akebia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
75 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
87
Accruals
82
Volatility
79
Size
66
Growth
64
Revisions
47
Issuance
35
Momentum
15

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Momentum (15): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AKBA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AKBA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00Oct 25Jan 26Apr 26Jul 26AKBAHigh $6.00Median $4.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $1.00Median $4.00High $6.00

The green dot is the last close — the median target sits +340.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 Aug 2026Leerink PartnersDowngradeMarket Perform—
7 Aug 2026Leerink PartnersDowngradeMarket Perform$1.00
1 July 2026HC Wainwright & Co.ReiteratesBuy—
1 July 2026HC Wainwright & Co.ReiteratesBuy$6.00
7 Apr 2026BTIGReiteratesBuy—
25 Feb 2026BTIGMaintainsBuy—
6 Feb 2026HC Wainwright & Co.ReiteratesBuy—
6 Feb 2026Piper SandlerMaintainsOverweight—
2 Dec 2025BTIGReiteratesBuy—
2 Dec 2025HC Wainwright & Co.ReiteratesBuy—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
29 Oct 2025BTIGMaintainsBuy—
4 June 2025HC Wainwright & Co.AssumesBuy$8.00
28 Apr 2025Leerink PartnersInitiatesOutperform—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025JefferiesInitiatesBuy—
14 Mar 2025HC Wainwright & Co.ReiteratesBuy—
14 Mar 2025Piper SandlerMaintainsOverweight—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AKBA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AKBA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Akebia Therapeutics, Inc. (AKBA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−45.4×

Cheaper than 98% of US stocks

Price / sales
1.2×

Cheaper than 66% of US stocks

Price / book
10.1×

Cheaper than 10% of US stocks

EV / EBITDA
−69.0×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
−21.4%

Higher than 11% of US stocks

Earnings growth (YoY)
−21.4%

Higher than 19% of US stocks

Gross margin
78.8%

Higher than 90% of US stocks

Operating margin
−5.5%

Higher than 27% of US stocks

Net margin
−13.5%

Higher than 18% of US stocks

Returns & dividend
Return on equity
−109.4%

Higher than 12% of US stocks

Return on assets
−1.1%

Higher than 39% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AKBA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
AKBAAkebia Therapeutics, Inc.$254.8M
75
ACBAurora Cannabis, Inc.$255.2M
34
ORGOOrganogenesis Holdings, Inc.$228.4M
52
EBSEmergent BioSolutions, Inc.$263.0M
90
SIGASIGA Technologies, Inc.$217.8M
42
CRDLCardiol Therapeutics, Inc.$217.4M
62
DERMJourney Medical Corp.$211.8M
67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Akebia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AKBA news & analysis

Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Seeking Alpha published the transcript of Akebia Therapeutics' Q2 2026 earnings call, covering the company's second-quarter financial results and management discussion. The headline and source indicate an earnings call transcript was released for the period.

Why it matters — AKBA watchers would care because the earnings call transcript provides direct insight into the company's quarterly performance and management's commentary.

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 5 Aug 2026negative

Akebia Therapeutics reported a Q2 loss of $0.02 per share, narrower than the Zacks Consensus Estimate of a $0.03 loss but worse than break-even earnings a year earlier. The company's revenue fell short of estimates for the quarter.

Why it matters — Akebia watchers would track this quarterly result as a measure of the company's financial progress against analyst expectations and prior-year performance.

Akebia Therapeutics Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

In its second-quarter earnings call, Akebia Therapeutics reported revenue growth for its Vafseo anemia treatment. The company also highlighted an interim clinical result from the VOICE study and progress across its kidney disease pipeline.

Why it matters — A AKBA watcher would care because the update indicates growth in Vafseo revenue and advancement of the company's kidney disease pipeline, including an interim clinical result from the VOICE study.

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

GlobeNewsWire · 5 Aug 2026positive

Akebia Therapeutics reported second quarter 2026 financial results, with Vafseo net product revenues rising to $21.3 million and more than 10,500 patients now on therapy. The company also initiated a Phase 2 open-label basket trial of ebribafusp for rare kidney diseases, and an interim analysis of the VOICE trial showed improved safety outcomes for Vafseo versus an ESA.

Why it matters — Akebia watchers would track this for signs of Vafseo commercial growth, pipeline advancement in rare kidney disease, and the VOICE trial's safety data supporting Vafseo against an ESA.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 3 Aug 2026neutral

Akebia Therapeutics granted inducement stock options to two newly hired employees covering an aggregate of 61,000 shares of common stock on July 31, 2026. The grants were made as an inducement material to each employee joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This equity-grant disclosure shows Akebia is using stock-based incentives to attract new hires, which AKBA watchers may track for potential dilution and hiring activity.

FAQ

Frequently asked questions about AKBA stock

What is the AKBA stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Akebia Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $1 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AKBA stock a buy right now?

Of the 5 analysts covering Akebia Therapeutics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Akebia Therapeutics, Inc. 75 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AKBA?

As at 22 Aug 2026, Akebia Therapeutics, Inc. ranks 75 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will AKBA stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +340.4% from the last close, and Ticker Nerd's factor model ranks Akebia Therapeutics, Inc. 75 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AKBA stock forecast for 2030?

No analyst covering Akebia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AKBA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $6 over the next 12 months.

How has AKBA stock performed over the past year?

Akebia Therapeutics, Inc. returned -71.5% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Akebia Therapeutics, Inc. do?

Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients impacted by kidney disease.

What is the latest news on AKBA?

The most recent item we track (Seeking Alpha, 6 Aug 2026): "Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Akebia Therapeutics' Q2 2026 earnings call, covering the company's second-quarter financial results and management discussion. The headline and source indicate an earnings call transcript was released for the period.

Company

About Akebia Therapeutics, Inc.

Akebia Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing therapies for patients impacted by kidney disease. Its lead product, Vafseo (vadadustat), is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for treating anemia due to chronic kidney disease in adults on dialysis. The company also maintains a pipeline targeting rare kidney diseases, including praliciguat, an sGC stimulator in Phase 2 for biopsy-confirmed focal segmental glomerulosclerosis, and AKB-097, a tissue-targeted C3d-Factor H fusion protein complement inhibitor planned for Phase 2 basket studies across complement-mediated conditions such as IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional candidates like AKB-9090 address acute kidney injury associated with cardiac surgery. Akebia Therapeutics Inc. supports its portfolio through licensing agreements, such as for Vafseo in Europe, and engages in post-marketing studies to expand clinical understanding and patient access in the dialysis community. Headquartered in Cambridge, Massachusetts, the company plays a key role in addressing unmet needs in the nephrology sector with innovative oral therapies and targeted pipeline advancements.

CEO Mr. John P. Butler MBA · 194 employees · United States · https://www.akebia.com